Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Trinidad & Tobago STEM News.
Press releases published on August 26, 2025
IAV Group Joins SDVerse to Accelerate Software Innovation and Drive the Future of Mobility
GlobeNewswire
·
August 26, 2025
DETROIT, Aug. 26, 2025 (GLOBE NEWSWIRE) -- IAV Group (“IAV”), a global leader in automotive engineering specializing in tech-driven, software-defined solutions, today announced it has joined SDVerse − the automotive industry’s first B2B marketplace …
Foresight: Continental and Eye-Net Collaborate to Enhance Road Safety Systems
GlobeNewswire
·
August 26, 2025
The project will evaluate the integration of Eye-Net’s advanced safety technology into Continental’s vehicle platforms Ness Ziona, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “ …
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
GlobeNewswire
·
August 26, 2025
– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA …
Global CAR T-Cell Therapy Market Set to Reach USD 29 Billion by 2029 | MarketsandMarkets™
GlobeNewswire
·
August 26, 2025
Delray Beach, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell Therapy market, valued at US$3.7 billion in 2023, stood at US$5.5 billion in 2024 and is projected to advance at a resilient CAGR of 39.6% from 2024 to 2029, culminating in a …
Altimmune to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will …
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
GlobeNewswire
·
August 26, 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
GlobeNewswire
·
August 26, 2025
Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamics AVIM therapy drove statistically significant reductions in systolic blood …
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
GlobeNewswire
·
August 26, 2025
HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
GlobeNewswire
·
August 26, 2025
Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, …
Draganfly Uniquely Positioned to Support Canada’s New $2 Billion Military Commitment to Ukraine with Advanced Drone and Tactical Capabilities
GlobeNewswire
·
August 26, 2025
Saskatoon, SK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an industry-leading developer of drone solutions and systems, today provided insight into its unique positioning to …
Draganfly stratégiquement positionnée pour soutenir le nouvel engagement militaire de 2 milliards de dollars du Canada envers l’Ukraine grâce à ses capacités avancées en drones et tactiques
GlobeNewswire
·
August 26, 2025
Saskatoon, SK, 26 août 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ : DPRO) (CSE : DPRO) (FSE : 3U8) (« Draganfly » ou la « Société »), un développeur de premier plan de solutions et systèmes de drones, a annoncé aujourd’hui sa position unique pour …
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire
·
August 26, 2025
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative …
Kraig Biocraft Laboratories Accelerates Operations into Two Rearing Centers in One of Southeast Asia's Premier Silk-Producing Regions
GlobeNewswire
·
August 26, 2025
ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that its two recently established rearing centers, located in the …
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 26, 2025
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 …
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
GlobeNewswire
·
August 26, 2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile …
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
GlobeNewswire
·
August 26, 2025
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission …
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor …
Syndax Announces Participation in September Investor Conferences
GlobeNewswire
·
August 26, 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of …
Climb Channel Solutions Partners with Coro to Enhance Cybersecurity Solutions
GlobeNewswire
·
August 26, 2025
EATONTOWN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce a strategic partnership with …
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …